Schizophrenia is a common mental disorder with a complex pattern of inheritance. Despite a large number of studies in the past decades, its molecular etiology remains unknown. In this study, we proposed a 'system-thinking' strategy in seeking the combined effect of susceptibility genes for a complex disorder by using paranoid schizophrenia as an example. We genotyped 85 reported single-nucleotide polymorphisms (SNPs) present in 23 genes for the dopamine (DA) metabolism pathway among 83 paranoid schizophrenics and 108 normal controls with detailed clinical and genetic information. We developed two novel multilocus approaches-the potential effective SNP combination pattern and potential effective dynamic effects analysis, by which three susceptibility genotype combinations were found to be associated with schizophrenia. These results were also validated in a family-based cohort consisting of 95 family trios of paranoid schizophrenia. The present findings suggest that the COMT and ALDH3 combination may be the most common type involved in predisposing to schizophrenia. Since the combination blocks the whole pathways for the breakdown of DA and noradrenaline, it is very likely to play a central role in developing paranoid schizophrenia.
Schizophrenia is the most common mental disorder with a lifetime risk of about 1% in the general population. 1 Although a genetic component is involved in the illness, neither association studies on candidate genes nor linkage analysis with large pedigrees for seeking a chromosomal region containing a susceptibility locus has consistently produced positive findings. 2 It has been thought that schizophrenia may be a typical complex disorder with multifactorial causes 1 and that it is genetically attributable to multiple interactive genes of small effect. 3 The complicated gene-gene interaction, heterogeneity of clinical presentation and numerous farraginous experimental data make it more difficult to draw a firm conclusion with genetic research work.
In most cases of complex disorders, a single gene of small effect is not sufficient to produce a clinical symptom, but their combined effect may confer additive genetic contributions. For instance, the Hopkins' scientists recently found that the interaction in mutations between RET and EDNRB was associated with Hirschsprung disease. 4 The idea of designing the present work is comparable to their work. In this study, we conducted the detection of single-nucleotide polymorphisms (SNPs) present in the genes coding for the enzymes involved in the dopamine (DA) metabolism pathway in attempting to examine whether their combined effects would confer a significant susceptibility to schizophrenia. We performed a two-step analysis. The first step was to carry out the systematic polymorphism screening for a genetic association between SNPs and phenotypes in 83 Chinese patients with paranoid schizophrenia and in 108 healthy individuals. The second step was to validate the initial findings resulting from the above case-control study by analyzing 95 family trios of paranoid schizophrenia.
Materials and methods

Subjects and clinical assessment
Since schizophrenia comprises different clinical subtypes and its manifestations vary from individuals to individuals, we selected patients only with paranoid schizophrenia in the present study. Initially, we recruited 300 unrelated Han Chinese patients, who were diagnosed as having a schizophrenic illness using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Of these 300 patients, 83 had suffered from paranoid schizophrenia. These paranoid schizophrenics were used as 'analyzing cohort'. The patients were clinically assessed by face-to-face interview using a series of inclusion and exclusion criteria (the criteria are available as Supplemental Material). The interviews were strictly conducted according to the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) manual. The CATEGO diagnostic software was applied to set up a database where clinical data were all stored. A total of 41 classical phenotypes (Table S1 of Supplemental Material) were output for further analyses. The demographic data of 83 patients with paranoid schizophrenia are shown in Table S2 of Supplemental Material.
In the case-control design, we totally recruited 108 unrelated healthy subjects for the genetic analysis. They were well matched to the patient group in gender, age, ethnicity and exclusion criteria.
All the patients and control subjects gave informed consent for participating in the genetic analysis and provided 5 ml of the whole-blood sample for isolation of genomic DNA.
Full-scale gene search on the DA metabolic pathway Schizophrenia is likely to involve complicated networks ranging from the metabolic pathways to the signaling pathways, such as the pathways of DA, serotonin, noradrenaline and glutamine. To search the susceptibility genes based on an overall point of view, every gene involved in the networks should be analyzed. In the preliminary study, we focused solely on investigating the metabolic pathway of DA.
There are at least 57 genes involved in the DA metabolism pathway in humans (Figure 1 ), but the Identification of the susceptibility-combing genes A multilocus approach was developed in identifying the susceptibility-combining genes for a multigenic complex disorder. This approach is different from the existing single gene association or linkage analysis methods. It represents such an idea as the genetic contribution to a complex trait may not be a simple linear sum over the effect size of all the individual genes involved. In this study, both nonlinear (eg epistasis) and linear interactions were taken into account. The method included the following steps.
SNP grouping
T could be defined, where M is the number of SNP sites to be considered and g k ð1 k M Þ is the genotypes of SNP sites. For any k, g k has its own range of definition. Using vector Q, a group of SNPs could be treated as a single unit, and the disease-associated SNPs were picked up, called as the potential effective SNP combination pattern (PESCP). A null hypothesis and alternative hypothesis were defined as follows:
where D and C represent disease and normal status, respectively, and P(Q|D) and P(Q|C) denote the probability that SNP combination pattern (SCP) Q appears in patients and controls, respectively. The accepted null hypothesis H 0 means that statistically Q is not associated with the change of susceptibility of disease; otherwise, Q is associated with the susceptibility change. Welch's t-ratio 5 T(Q), which is defined in formula (2), was used to test for the above hypothesis.
Usually, the dimensions of polymorphism vector Q are high, and thus, the number of possible SCPs is often very large. Genetic algorithm (GA) 6, 7 was used to speed up testing for the hypothesis and finding out PESCPs. In the GA, Q served as 'chromosome'. Normally, the statistical significance of the SCP Q is not equivalent to the SCP's practical significance Q when it is associated with a disease. 8 The statistical significance means that the observed mean differences are not likely to result from sampling error and the practical significance indicates whether the difference is biologically meaningful.
Considering the practical significance, we defined the fitness of Q as follows:
where l is an adjustable parameter that makes the two terms of approximately in the same scale, but the first term plays the major role. The first term of is closely related to the t-test and a P-value (ie (p1-p2)/ sqrt[var(p1)/n1 þ var(p2)/n2]), and it can be used to assess the statistical significance of a risk change. The second term is used to assess the magnitude of the risk change. After the test, genotypes SNP1 ¼ G/T, SNP2 ¼ A/T and SNP3 ¼ C/T may be associated with higher or lower susceptibility to the disease.
An example is given here to explain the subtle difference between the statistical significance and the practical significance. Suppose there are two observations about risk change, one 0. 
Clustering effective SNPs and finding a subtype of disease
Many of the PESCPs found in the first step may be very similar, and only a few sites show different. The purpose of clustering SNPs was to allow similar PESCPs, which may represent a certain subtype of disease, to form a cluster so that the redundancy can be eliminated and the complexity of the analysis would be reduced. The SNP-clustering method was based on a similarity measure. 9 A Q-match vector could be defined as S ðQÞ ¼ ½s 1 ; s 2 ; . . . ; s N T where N is the total number of samples in S. For any sample k(1rkrN) if k has the SCP Q, then s k ¼ 1; otherwise, s k ¼ 0. The similarity function rðQ 1 ; Q 2 Þ between Q 1 and Q 2 can be defined as
Formula (4) was used for the clustering of SNPs. 10 
Background gene analysis
In the above two steps, we can only find out which gene combination may correspond to a high or low susceptibility to schizophrenia, but the background The dynamic analysis began with a hypothesis test. Suppose the 23 genes studied in this work were the potential susceptibility genes of schizophrenia, then consider a subset S 0 of sample set S. If 8s 2 S 0 , s is a Q-sample, that is, s has SCP Q, then S 0 was defined as a Q-set, denoted as S 0 ¼ HSðS; QÞ. Each pair of samples in S 0 was defined as a pair of relative homogeneous samples. Owing to the effect of the genotype change of SNP site g, genetic backgrounds of samples should be kept as similar as possible even though they may not be exactly identical. We always set an SCP Q, which does not contain g, as a genetic background. The problem then showed that given an SCP Q, what kind of changes in susceptibility would occur after the genotype of g changed. By introducing Q into the analysis, genes were no longer isolated and gene functions were always studied in the context of a gene network. Q did not necessarily contain all the SNPs in question, but it just contained the appropriate number of sites to ensure sufficient samples all the time (note: all of the samples are now homogeneous to some extent as they all have SCP Q) for drawing a statistical conclusions. Let q 1 and q 2 be two possible genotypes of g. Denote disease status as D and nondisease status as C, respectively. Define null and alternative hypotheses as follows: 
We can obtain
As a result, the hypothesis test can be designed as follows:
If 
To implement the calculation of PðT g ðq 1 ; q 2 jQ; SÞ40Þ and PðT g ðq 1 ; q 2 jQ; SÞo0Þ, both bootstrap 10, 11 and Bayesian posterior sampling method 12, 13 were used. All statistically significant effects of genotype changes would be picked up, which was called the potential effective dynamic effects (PEDEs).
Permutation test
To address the multiple comparison issue and for the statistical evaluation of PESCPs and PEDEs, permutation tests were carried out. After running GAs, a long list of PESCPs together with their fitness values would be seen. In order to obtain a valid statistical evaluation, a P-value for each PESCP was revealed as follows: Pvalue ðQ ðjÞ Þ ¼
where If:g is indicator function, which assigns the value 1 to a true statement, and the value 0 to a false statement:
A similar permutation test is used to obtain the P-values for PEDEs.
Result validation by using independent family-based genotyping data Permutation test could be used all the time to evaluate statistical evidence of supporting PESCPs and PEDEs. If an additional independent data set were available, however, it would be used to validate the result for strengthening the conclusion.
A total of 95 Chinese family trios, consisting of fathers, mothers and affected offspring with paranoid schizophrenia, were enrolled for validating the positive results obtained in the above analysis. The affected offspring all comprised the patient set (PS). Their simulated sibs could be created as control sets (CS i (i ¼ 1,y,k)) according to biological rules from their parents' genotyping data. For a given PESCPQ, the number of the Q-individuals who had SCP Q was counted for every CS, and as a result, a null distribution of the number of the Q-individuals could be obtained. The number of the Q-individuals in PS was then counted and compared to the null distribution to obtain a corresponding P-value. A similar procedure was used to obtain P-values for PEDEs. The only difference from the PEDE analysis was that what had to be compared was the ratio of two numbers, corresponding to the number of individuals with two different SCPs, to its null distribution.
Results
PESCP analysis
By setting l ¼ 0.01 and initial population in different values, 100 PESCPs were picked up. Data were permuted 100 times and the permutation test was carried out to evaluate the statistical significance of these 100 PESCPs. The resulting P-values were all less than 0.01.
These 100 PESCPs were clustered and the clustering results were shown in Figure 2 . Some potential subtypes of paranoid schizophrenia as well as their typical PESCPs were given in Table 1 . The corresponding gene and SNP site of each component of the polymorphism vector was listed in Table 2 .
According to the results, PESCP [COMT(rs174682), 
PEDE analysis
By setting l ¼ 0.01 and initial population in different values, 100 PEDEs were picked up based on a Bayesian analysis scheme. Data were permuted 100 times and permutation test was carried out to evaluate statistical significance of these 100 PEDEs. The resulting P-values were all less than or equal to 0.01. Some typical PEDEs were listed in Table 3 .
As shown in Table 3 , some PEDEs of potential interest included were as follows:
(rs581105) changed from 0(T/T) to 1(T/G), disease susceptibility would then increase. And as Figure 2 Clusters of 100 PESCPs.
[ALDH3(rs917520), ALDH3(rs105147), ALDH3 By setting l ¼ 0.01 and initial population in different values, 100 PEDEs were searched again based on a bootstrap scheme. Data were permuted 100 times to evaluate the statistical significance of these 100 PEDEs. The resulting P-values were all less than or equal to 0.010. After the permutation test and comparison with the results obtained by Bayesian Susceptibility to schizophrenia Table 2 . 
rs165688, rs165599, rs933269, rs740603, rs174694, rs174682, rs165656 ALDH3 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) rs887241, rs917520, rs2010404, rs105147, rs598156, rs581105, rs475325, rs15518, rs1003777, rs1551888, rs1871031 ADH (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) rs1693425, rs1042026, rs1789882, rs1229982, rs1229984, rs1042758, rs1800760, rs1154413, rs1154414, rs729147, rs971074, rs284786, rs894369, rs284787 TYR (34) rs1042602 TPO (35) (36) rs1399390, rs938328 MAO (37) (38) (39) rs6323, rs1801291, rs1040399 DAO (40) (41) rs1049748, rs1049793 AOX1 (42) (43) rs1405984, rs1527945 DDC (44) (45) (46) (47) rs921450, rs1451374, rs1451373, rs6263 HGD (48) rs2042482 DBH (49-50) rs2005663, rs2007153 GSTZ1 (51) rs1046428
a SNP ID no. of the gene polymorphism in NCBI database (http://www.ncbi.nlm.nih.gov/SNP/).
Association analysis in schizophrenia Q Xu et al scheme, we became aware that the following PEDEs would be more reliable.
(1) ADH(rs1042026) changed from 0(C/C) to 1(C/T) and disease susceptibility would then increase. 
Result validation
In 95 family trios tested, genotyping data for COMT(rs174682), ALDH3(rs581105), ADH(rs1042026), ADH(rs1789882), ADH(rs1229982), ADH (rs1229984) and MAO(rs1801291) were collected.
The permutation test was performed 100 times. The results demonstrated that the P-values for PESCP [COMT(rs174682), ALDH3(rs581105)] ¼ [1(T/G), 1(T/G)] and PESCP [COMT(rs174682)] ¼ [2(G/G)
] turned out to be less than or equal to 0.01, strongly supporting our initial conclusion. The PEDE analysis showed that if ADH(rs1042026) changed from 0(C/C) to 1(C/T), the disease susceptibility would then increase, and this susceptibility change was statistically significant (Po0.01). Although the P-value for PESCP 
The locus of g is illustrated by '*' in column Q. b Locus with '-' will not be considered in the analysis. 14 Moreover, most of them lack a clear mode of inheritance and usually show genetic heterogeneity. All these factors make it very difficult to identify susceptibility genes for a complex disease.
With the recent advances in molecular biology, two kinds of approaches have been developed: the genedriven method (eg double knockout animal) and the trait-driven method (eg quantitative trait locus (QTL) mapping). 15 Although these methods have provided more or less help in seeking the diseases-related genes for a complex disease, they still have limitations in some aspects. A complex trait may involve many related genes and their possible combinations shown in the joint analysis of multiple loci could be so numerous that one can hardly use the double knockout animal method to simulate all the combinations in a short time. Furthermore, we cannot expect to knockout all the genes of interest, especially the housekeeping genes. The QTL mapping has been used as a powerful tool for identifying disease-related genes, 16 but at present it is confined to the two-locus interactions. 15 Identification of the genes responsible for similar phenotype remains very difficult. 17 To circumvent this problem, comprehensive concerted efforts among all relevant knowledge, including clinical medicine, genetics, biochemistry, statistics, mathematics and bioinformatics, are in urgent need. A novel concept or approach should be incorporated in a research program to maximize the chances of pinpointing the genuine susceptibility genes from a large number of possible loci for complex disorders, and in other words, to discriminate between marginal signals and background noise within extremely large, diverse and complex data sets. 18 To achieve this goal, however, there are at least three critical areas being taken into account and improved: (1) systematical and thorough study of genes; (2) strict clinical assessment and subgrouping of affected individuals; and (3) new analytical methods used to extract the combined effects of all the susceptibility genes from the data warehouse. Our strategy of genetic research into schizophrenia is just based on these points.
Importance of clinical sampling
Schizophrenia manifests itself in signs and symptoms that nearly include the entire range of psychopathology. 19 Thus, clinical sampling and defining phenotypes are critical to the genetic analysis of schizophrenia due to its heterogeneity of clinical presentation. This heterogeneity has prompted psychiatrists to propose many hypotheses of grouping subtypes, 20 but the clinical classification of paranoid (or delusional), hebephrenic (or disorganized), undifferentiated, catatonic and simple subtypes is still accepted and used mostly in different diagnostic systems, such as ICD-10 (WHO, 1992) 21 or DSM-IV (APA, 1994). 22 There are two important considerations in clinical sampling and phenotype selection. First, the diagnostic criteria applied for the research will influence the quantity and quality of the clinical sampling. In this study, we use the ICD-10 diagnostic criteria and its structured interview tool SCAN 23 to ensure the accuracy and strictness of the diagnoses. Second, some subtypes (for example, the catatonic subtype or the simple subtype) are more heterogeneous in clinical presentation and thus may affect the homogeneity of clinical samples in a sense. We excluded these patients and only analyzed paranoid schizophrenics without or with some atypical disorganized features.
Schizophrenia with an onset earlier than 12 years old or later than 45 years old is categorized as children schizophrenia and late-life schizophrenia, respectively. Owing to their atypical clinical features or possible different underlying mechanisms, we excluded these patients from our study.
Schizophrenic patients with a disease duration longer than 15 years are also excluded from the study. It seems to be an arbitrary selection, but the reason for this exclusion is that these patients were generally in recurrent episodes and hospitalizations, and presented mainly residue symptoms, which is difficult to make accurate diagnosis and collect complete psychopathological information.
Why the DA metabolism pathway given priority of investigation? DA is a key neurotransmitter in the central nervous system. The dopaminergic hypothesis has been very influential in schizophrenia research 24 in the past 50 years. It is a common sense that dopaminergic overactivity may play a crucial role in the pathogenesis of schizophrenia, at least in developing positive symptoms. It has been reported that polymorphisms of many genes are likely to affect DA biosynthesis, 25 catabolism 26 and response to neuroleptic drugs, 27 suggesting that genetic variability may underlie the development of the disease.
Use 'phenotype' as an exploratory measure to identify associated phenotypes Since phenotype information had not been used to search for PESCPs and PEDEs, this information could be used as an exploratory measure to identify associated phenotypes once a validated association has been found. One believed that if a PESCP or PEDEs were truly positive, it should then be able to influence certain phenotypes. In such cases, more severe symptoms should be shown in patients with a susceptibility-associated PESCP than in those without it. In order to implement this, for any given PESCP Q, all the patients were classified into two groups. Patients in group 1 has SCP Q and those in group 2 did not. The number of patients in group 1 was denoted as n 1 and that in group 2 as n 2 . For a specific quantified phenotype, assume that its mean and standard error are m 1 and s 1 in group 1, and m 2 and s 2 in group 2, respectively. Again, Welch's t-ratio
could be used to investigate if there was any difference between groups 1 and 2 on this given phenotype. Alternatively, we could carry out a t-test directly. In many cases, quantified phenotypes had a skewed distribution, and outliers were often encountered. To make the comparison robust, the t-test should be replaced by the rank-sum test. 28, 29 By picking up all the phenotypes showing significant differences between two groups, we could know which phenotype might be influenced by PESCP Q.
Although it is quite possible that a disease may show many kinds of symptoms due to the complexity of the disease mechanism, only a few are associated with a PESCP of interest. If this were the case, additional clues to the functions of the PESCP and its related genes could then be obtained. Similarly, the PEDEs' results could be identified in the same way. The patients with SCP Q were selected and were subgrouped according to g's genotype. Using either the t-test or the rank-sum test, the phenotypes influenced by the change of a genotype could be obtained.
In the present work, both PESCPs and PEDEs' results were identified by phenotype data of patients. All phenotypes with P-value less than or equal to 0.05 were picked up. We found that PESCP [COMT (rs174682),
] is a subtype with lower schizophrenia susceptibility than normal people.
While checking PEDE, we first checked COMT(rs174682). As COMT(rs174682) changes from 1(T/G) to 2(G/G), onset was delayed, consistent with the previous result. In the second PEDE, we checked, as ALDH3(rs581105) changes from 1(T/G) to 2(G/G), manic-and autistic-related symptoms are severed, suggesting the potential role of ALDH3 in manic-and autistic-related metabolism. In PEDE ADH(rs1042026), as ADH(rs1042026) changes from 0(C/C) to 1(C/T), psychotic-related symptoms seemed to be elevated. Although MAO was not identified as significant according to validation based on independent family-based genotype data, we still checked it with phenotype data. This gene seems to be associated with negative and psychoti-related symptoms.
Innovation of data analysis methods
Both the PESCP analysis and the PEDE analysis are multilocus approaches. The unit to be analyzed is a group of SNPs located either in the same chromosome or in different chromosomes. This reflects the basic concept that complex diseases may result from complex (linear and nonlinear) interactions among a large number of various factors, and may be controlled by and through the networks. It is far from enough to study each factor separately in elucidating the pathogenesis of a complex disease as being a simple linear consequence of their combined effects. Treating disease-related SNPs (either from a single chromosome or from many different chromosomes) as a group makes our methods different from traditional linkage and association analyses. It has long been noted that the analysis of gene's function in the context of other gene's is necessary. 30 Several approaches of studying genes in combination have been developed, including the combinatorial partitioning method (CPM), 31 the multifactor-dimensionality reduction (MDR) 32 and the cellular automata approach (CAA). 33 However, our methods are characterized by the following points that are different from others. First, the present methods can explicitly tell how the combined effect of multiple disease genes may affect a disease, that is, which genotype patterns are significantly associated with a high or low susceptibility, and how the susceptibility would change if the genotype of a specific site changed. Second, the present methods have implemented efficient algorithms. We have analyzed tens of practical sites together. Such a kind of studies has not been documented and thus cannot be implemented by adopting an enumeration strategy used by methods like CPM. 31 The capability of any method aiming to pick up the gene combination of potential interest has been limited by a sample size. In this paper, we proposed not only a novel concept for the genetic analysis, such as PESCP and PEDE, but also a series of statistical models and algorithms to implement this concept in making full use of limited samples. The principle of our model is that if data are sufficient to draw a statistically significant conclusion, then we do so; otherwise, no conclusion would be made. The model is implemented by GA-based algorithms. In the algorithms, the statistical significance of results is guaranteed by different P-value equivalent terms. This strategy actually makes a compromise between the need to study complex gene interactions and the limited number of available samples. In this way, we can extract as much information from a data set as possible. Despite the application of a statistical significance, we have also introduced additional items to keep the significance more practical.
Several methods have been developed to pick up the gene combination of potential interest from a limited sample size, including CPM, MDR, CAA and PESCP, PEDE, but these methods cannot solve the problem of the inflation of a false-positive rate. In this study, we have proposed a strategy to validate the results. If no other information other than the samples is at hand, the permutation test is always available to insure a statistical significance for PESCPs and PEDEs. Of course, the most reliable way is to replicate the initial results using an independent data set. In this study, we independently collected some familybased genotyping data to validate the results. The relationship between genotypes and phenotypes shows that if a genotype is more likely to cause disease, it will produce more severe phenotypes. To incorporate phenotype information in PESCP and PEDE analyses, we have combined different sources of information, and more reliable results were then obtained. In fact, we have put forward a new strategy to study complex diseases by combining genotype information with incomplete phenotype information. This is a useful procedure especially when an independent data set is not available. To the best of our knowledge, the validation issue is still a serious and unsolved problem for many gene combination methods such as MDR 32 and CAA. 33 Combined genotype effects of the dopaminergic pathway In this study, we found that the genes coding for COMT, ALDH3, MAO and ADH were associated with the susceptibility to schizophrenia. As these enzymes are all related to the breakdown of DA (Figure 1 ), DA could accumulate in the central nervous system when their activities decreased. This finding tends to support the hypothesis for dopaminergic overactivity in schizophrenia. One believes that the combined effect of COMT and ALDH3 may play a central role in developing paranoid schizophrenia. The two-gene combination seems to have blocked the whole pathways for the breakdown of catecholines, including DA, noradrenaline and adrenaline, although it is unlikely to affect the conversion of DA to noradrenaline. The blockage may eventually lead to the accumulation of both DA and noradrenaline. These two neurotransmitters are very important in mediating a variety of functions in the central nervous system, such as motor control, cognition, emotion, memory procession and endocrine modulation. 34 It is well known that the mesolimbic DA system modulates emotion, 35 while the mesocortical DA system is involved in cognition performance, including thinking, sensation, comprehension, learning and reasoning. 36 The DA dysfunction in either of these two systems could trigger a schizophrenic illness. 37, 38 In an animal model reported previously, the stimulation of dopaminergic neurons projecting to the limbic system can cause many schizophrenia-like symptoms. What type of symptoms is presented depends on the stimulated region. The stimulus on the lateral side of amygdaloid nuclear and the median of callosal gyrus can cause phobia, and that on the medial side of amygdaloid nuclear and anterior cingulate can cause an aggressive reaction. This may be a possible reason for a genotypic association between the COMT locus and violence in schizophrenia. 39 Neurochemical and neuroanatomical investigations suggest a major role of noradrenaline in schizophrenia, 40 based on a clear relation with cognitive functions, 41 emotion, 42 learning and memory of the patients. Moreover, the dopaminergic system and the noradrenalinergic system have a functional relationship in the brain. 43 Another combination found in the present work is the MAOA gene in males. As the MAOA gene is located in the p11.23 band of the X chromosome, it is possible that the involvement of MAOA may produce a gender difference in developing schizophrenia. Brunner et al 44 found that the MAOA gene was associated with the aggressive and violent behavior in affected patients with Brunner syndrome. MAOA catalyzes the oxidative deamination of biogenic amine. It is involved not only in the breakdown of DA but also in the catabolism of serotonin, benzedrine, noradrenaline, histamine and some amino acids. A low level of MAO activity has been found in patients suffering from schizophrenia. 45 Possibly, tryptamine, N,N-dimethyltryptamine, benzedrine, noradrenaline and histamine may in turn be accumulated in the body. N,N-dimethyltryptamine can cause hallucination, and benzedrine is a typical psychotomimetic agent that can induce hallucination and delusion. Histamine can strongly strengthen excitement signal and it is related with emotion control. The serotonin hypothesis for schizophrenia was put forward earlier than the dopamine hypothesis. It can date back to experiences with D-lysergic acid diethylamide tartrate (LSD) in the 1950s. Disturbances of the serotonergic pathway have been implicated in schizophrenia. Antipsychotics that block 5-HT receptors in the brain are effective in reducing some psychotic symptoms. Some experiments have demonstrated the relationship between MAOA and cognitive or behavioral phenotype in several mental disorders, including bipolar disorder, 46 panic disorder and antisocial behavior in victims of maltreatment. 47 The last factor contributing to schizophrenia is rooted at the ADH gene. Although ADH is not located in a key position in the DA pathway, it is involved in the metabolism of many substances, including alcohol, fatty acids, bile acid, glycerolipid and gluconeogenesis. The patients with alcoholic dependence or alcoholism have similar symptoms to schizophrenia, such as hallucination, delusion and personality disorder, etc.
In conclusion, we have tried to provide a newer idea and a novel strategy to study systematically a complex disorder like schizophrenia. Based on this concept, we found that three groups of genotype combinations were associated with the susceptibility of schizophrenia. However, these results were given solely through the genetic analysis, and their pathophysiological explanations remain needed with further efforts.
The future
As mentioned above, schizophrenia is related not only to the dopamine metabolism pathway but also to the pathway of serotonin, glutamic acid, etc as well as to their signaling pathways. The analysis of SNPs in the genes involved in those pathways is in progress.
The work presented here is just a preliminary to a long period of research into the mechanism of complex disorders. To make further progress, there is a need to: (1) collect as many affected individuals as possible, 48 who should be assessed strictly based on a diagnostic criteria, (2) conduct further function studies of the susceptibility genotype combinations, and (3) apply the same strategy to investigate other typical complex disorders.
